---
title: "Palvella Therapeutics Advances Phase 3 Study on QTORIN Gel for Rare Disease"
description: "Palvella Therapeutics, Inc. is advancing a Phase 3 clinical study titled ‘SELVA’ to evaluate the safety and efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel for treating microcystic lymphatic malformat"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262951167.md"
published_at: "2025-10-27T19:15:42.000Z"
---

# Palvella Therapeutics Advances Phase 3 Study on QTORIN Gel for Rare Disease

> Palvella Therapeutics, Inc. is advancing a Phase 3 clinical study titled ‘SELVA’ to evaluate the safety and efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel for treating microcystic lymphatic malformations. The study involves approximately 40 participants and aims to assess treatment effects over 24 weeks. It began on January 16, 2024, with primary completion expected in 2025. Positive results could influence Palvella's stock performance and attract investor interest, especially with FDA involvement. Competitors in the rare disease sector are also monitoring the study's progress.

Palvella Therapeutics, Inc. is conducting a Phase 3 clinical study titled ‘SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations.’ The study aims to assess the change in microcystic lymphatic malformations IGA after 24 weeks of treatment with QTORIN 3.9% Rapamycin Anhydrous Gel in approximately 40 participants, with the option for extended treatment.

The intervention being tested is QTORIN 3.9% Rapamycin Anhydrous Gel, a drug designed to treat microcystic lymphatic malformations by evaluating its safety and efficacy over a 24-week period.

The study follows an interventional design with a single-group model and no masking, focusing primarily on treatment. This straightforward design aims to provide clear insights into the drug’s effectiveness.

The study began on January 16, 2024, with its primary completion anticipated in 2025. The most recent update was submitted on July 22, 2025, indicating ongoing recruitment and progress.

This study could significantly impact Palvella Therapeutics’ stock performance and investor sentiment, particularly if the results are positive, given the involvement of the FDA Office of Orphan Products Development. Competitors in the rare disease treatment space will be closely monitoring these developments.

The study is currently ongoing, with further details available on the ClinicalTrials portal.

### Related Stocks

- [PVLA.US - Palvella Therapeutics](https://longbridge.com/en/quote/PVLA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Palvella Expands QTORIN Gel Program for Rare Disease | Palvella Therapeutics (PVLA) announced on September 24, 2025, the expansion of its QTORIN™ 3.9% rapamycin anhydrous gel  | [Link](https://longbridge.com/en/news/258825769.md) |
| Maine CDC reports 4 additional cases of measles have been confirmed in Maine | Maine CDC reports 4 additional cases of measles have been confirmed in Maine | [Link](https://longbridge.com/en/news/276164223.md) |
| 10:02 ETThe Center for Cancer and Blood Disorders Revolutionizes the Delivery of CAR-T Cancer Treatments for Texas Patients | The Center for Cancer and Blood Disorders has launched a program to deliver CAR-T therapy in community practices across  | [Link](https://longbridge.com/en/news/276139832.md) |
| UroGen Pharma CEO Touts ZUSDURI Launch Momentum, J-Code Boost and Billion-Plus Peak Sales Target | UroGen Pharma's CEO Liz Barrett highlighted the company's focus on urothelial cancer and the commercial launch of ZUSDUR | [Link](https://longbridge.com/en/news/276020468.md) |
| How Regular Dental Visits Support Oral Health in Vero Beach, FL | Regular dental visits are crucial for maintaining oral health and preventing serious medical issues. They help prevent c | [Link](https://longbridge.com/en/news/276145403.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.